The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of protocol mandated testing in E4A03, a randomized phase III study of CC-5013 plus dexamethasone versus CC-5013 plus low-dose dexamethasone in multiple myeloma (MM).
Natalie Scott Callander
Research Funding - Millennium
Susanna J. Jacobus
No relevant relationships to disclose
Matthias Weiss
No relevant relationships to disclose
Shaji Kumar
No relevant relationships to disclose
Rafael Fonseca
No relevant relationships to disclose
David Samuel DiCapua Siegel
No relevant relationships to disclose
Michael S. Katz
No relevant relationships to disclose
Rafat Abonour
No relevant relationships to disclose
Michael E. Williams
No relevant relationships to disclose
Philip R. Greipp
No relevant relationships to disclose
Vincent Rajkumar
No relevant relationships to disclose